{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-066370","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.963551+00:00","generated_at":"2026-05-22T05:23:20.587514+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Monte Rosa Q1 net income $46.9M on Novartis revenue; pipeline advances","bullets":["Net income of $46.9M vs net loss of $32.0M a year ago; collaboration revenue $84.9M from Novartis.","Cash, equivalents, and securities $331M; expected to fund operations into 2028.","MRT-6160 (VAV1) advancing to Phase 2 with Novartis; up to $2.1B in milestones.","MRT-2359 (GSPT1) shows clinical signals in CRPC; additional data expected H2 2025.","IND filing for MRT-8102 (NEK7) on track H1 2025; CDK2/CCNE1 IND planned for 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-066370","json":"https://secwatch.observer/filing/0000950170-25-066370.json","markdown":"https://secwatch.observer/filing/0000950170-25-066370.md","text":"https://secwatch.observer/filing/0000950170-25-066370.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000095017025066370/0000950170-25-066370-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000095017025066370/glue-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:23:20.587514+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}